Institute of Life Science 2 Internal Atrium

Dr Marcos Quintela Vazquez

Research and Development Innovation Officer, Medicine

Telephone number

+44 (0) 1792

Research Links

Available For Postgraduate Supervision


Based at the Medical School, Dr Quintela is a Research and Development Innovation Officer in the Reproductive Biology and Gynaecological Oncology (RBGO) research group. Dr Quintela graduated from his bachelor’s degree at the University of Salamanca (Spain) in 2012. He then undertook his master’s degree in Biotechnology at the Autonomous University of Barcelona (Spain) and in 2014 he moved to the UK to start a PhD in Nanomedicine at Swansea University. His PhD was undertaken in partnership with the Houston Methodist Research Institute, where he spent two years working as a Graduate Research Fellow. After completing his PhD, Marcos joined the College of Medicine as a researcher, first working within Data Science and now as part of the RBGO group.

Areas Of Expertise

  • Cell and molecular biology
  • Genomics and epigenomics
  • Bioinformatics, omics data analysis
  • Reproductive biology and gynaecological oncology
  • Drug development

Career Highlights

Teaching Interests

Marcos lectures for the Nanomedicine MSc course in a wide range of modules.


Marcos’ current research involves the identification and characterization of novel epigenetic drugs, ascertaining their potential as new routes for ovarian cancer treatment. Dr Quintela has expertise in the epigenetic profiling of ovarian cancer samples; greater understanding of this area will inform and benefit future therapeutic choices.

• Quintela M, Sieglaff DH, Gazze AS, Zhang A, Gonzalez D, Francis L, et al. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine Nanotechnology, Biol Med 2019;17:254–65. doi:10.1016/j.nano.2019.01.017.

• Younas K, Quintela M, Thomas S, Garcia-Parra J, Blake L, Whiteland H, et al. Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. J Mol Med 2019;97:1315–27. doi:10.1007/s00109-019-01809-6.
• Friguglietti J, Das S, Le P, Fraga D, Quintela M, Gazze SA, et al. Novel Silicon Titanium Diboride Micropatterned Substrates for Cellular Patterning. Biomaterials 2020;244. doi:10.1016/j.biomaterials.2020.119927.


Marcos has worked with several international academics and continues to do so on a number of collaborative projects, including Dr Francesca Taraballi (Houston Methodist Research Institute) and Dr Fatima Merchant (University of Houston). His current project involves significant industrial partnerships with GSK and Porvair, amongst other national and international companies.